Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Exposure related observations in humans: other data

Currently viewing:

Administrative data

exposure-related observations in humans: other data
Type of information:
experimental study
Adequacy of study:
key study
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: Adopted according to OECD SIDS

Data source

Reference Type:
study report
Report date:

Materials and methods

Type of study / information:
Human skin irritation and sensitization
Endpoint addressed:
skin irritation / corrosion
skin sensitisation
Principles of method if other than guideline:
Repeated insult patch tests
GLP compliance:
not specified

Test material

Constituent 1
Chemical structure
Reference substance name:
Ammonium mercaptoacetate
EC Number:
EC Name:
Ammonium mercaptoacetate
Cas Number:
Molecular formula:
ammonium sulfanylacetate
Details on test material:
- Name of test material (as cited in study report): Ammonium thioglycolate
- Analytical purity: no data


Details on study design:
Repeated insult patch tests were used to evaluate the skin irritation and sensitization potential of 14.4% Ammonium Thioglycolate in a total of 240 subjects (32 males, 208 females, 18-69 years old). A panel of 240 subjects was patch tested with 14.4% Ammonium Thioglycolate. On Mondays, Wednesdays, and Fridays, the test substance was applied (0.2 ml, semi-occlusive patch) for 24 h to an area, between the scapulae and waist, adjacent to the midline. New sites were used for subsequent induction patch applications.

Patch removals on Tuesday and Thursday were each followed by a 24 h non-treatment period, and removals on Saturday by a 48 h non-treatment period. Each site was scored prior to application of the next patch according to the scale: 0 (no evidence of any effect) to 4 (severe, defined as deep-red erythema with/without vesiculation or weeping). The test procedure was repeated for a total of nine applications.

After a 15 to 19 day nontreatment period, challenge patches were applied to new test sites. Reactions were scored at 24 and 48 h post-application. Any subject with a reaction during the challenge phase that was stronger than mild erythema (score = 1) was rechallenged 28 days later at a new test site.
Exposure assessment:
not specified

Results and discussion

A total of 20 subjects withdrew from the study, during induction phase, for reasons that were unrelated to treatment. Four of the subjects who withdrew had reactions to 14.4% Ammonium Thioglycolate: barely perceptible erythema (2 subjects), mild erythema with mild oedema (1 subject), and moderate erythema (1 subject). Of the 220 subjects who completed the study, 4 were not available for 24 h challenge readings.

In these subjects, reactions were not observed during 48 h challenge readings nor during the induction phase. Twelve of the 220 subjects had reactions to 14.4% Ammonium Thioglycolate only during the induction phase. Reactions classified as barely perceptible erythema score = +) predominated. Stronger reactions were observed in 3 subjects: 1 subject with mild erythema (score = 1) and 2 subjects with moderate erythema (score = 2). Reactions to not more than two induction applications were observed. Seven subjects had reactions to 14.4% Ammonium Thioglycolate only during the challenge phase. Reactions classified as barely perceptible erythema predominated. A stronger reaction, moderate erythema with mild oedema (score = 2e; 48 h reading), was observed in 1 subject. Reactions were not observed after the second challenge.

Applicant's summary and conclusion

The authors concluded that 14.4% Ammonium Thioglycolate did not induce clinically meaningful irritation or any evidence of induced allergic contact dermatitis in human subject.